Please upgrade your browser.
The pivotal Phase III study will evaluate as the primary endpoint the overall survival of advanced renal cell carcinoma patients treated with IMA901 in combination with Pfizer's Sutent(R) (sunitinib malate) versus Sutent(R) alone.
The urinary system under attack does not perform to its optimal level and WBC escape through the urine during this time.
The medicine has successfully been tested for the treatment of breast, bone, liver, and kidney cancer, which are the most resistant cancers...
Surgeons at University of Rochester Medical Center in New York state, US, have become the first in the country to use a new infrared imaging technique combined with robot-assisted surgery to remove kidney cancer.
"One of the draw backs to the use of interluekin as an anti cancer agent is its toxicity. When given intravenously in the sort of dose that you had to administer to have an effect on kidney cancer, it was extremely toxic and even dangerous..."
Snapshots taken during the 2011 National Patients & Survivors Conference held at M. D. Anderson Cancer Center, Houston, Texas, Saturday, April 9, 2011.
Despite novel targeted agents, prognosis of metastatic renal cell cancer (RCC) remains poor, and experimental therapeutic strategies are warranted
This is a medical milestone discovered here in Rochester.
Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study
Despite novel targeted agents, prognosis of metastatic renal cell cancer (RCC) remains poor, and experimental therapeutic strategies are warranted.
...recent advances in relevant biomarkers to predict efficacy of biologic therapies and elaborates on their relevance in the clinical management of patients with solid tumor malignancies.
|Powered by NeonCRM|